Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AtTEnd: Atezolizumab in Advanced Endometrial Cancer
NCT03603184Phase 3Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Oct 2018
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in endometrial cancer (EC) comparing Atezolizumab + Chemo with Placebo + Chemo (2 arms). Primary endpoints: Progression-Free Survival in dMMR population, Progression-Free Survival (Overall Population) and 1 more. Started Oct 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03603184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603184.